x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230524
| Product Information | |
|---|---|
| CAS No. | 1434635-54-7 |
| Synonyms | ND630 ACC1 ACC2 |
| Formula | C28H31N3O8S |
| Molecular Weight | 569.63 |
| Product Description | ND-630 (NDI 010976) is a highly specific, reversible inhibitor of ACC1 (IC50 = 2 nM) and ACC2 (IC50 = 6 nM). ND-630 interacts within the ACC phosphopeptide acceptor and dimerization site to prevent dimerization of ACC. Because the dimerization site is not conserved among other mammalian carboxylases, ND-630 lacks the ability to inhibit other mechanistically-related enzymes. In rats with diet-induced obesity, ND-630 reduced hepatic steatosis, improved insulin sensitivity, and reduced weight gain, suggesting ACC inhibition may be useful in treating metabolic disorders, including type 2 diabetes mellitus, and fatty liver disease. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 99% |
| Shipping | Shipped at room temperature. |
| Storage | Store at -20 °C for up to a year. Dissolve in anhydrous DMSO and store DMSO stock solutions at 4 °C for a couple of days or store stock solutions at -20 °C in aliquots for up to a month. Avoid freeze/thaw cycles of solutions. |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
